NTLA-2002 (lonvoguran ziclumeran)
Hereditary Angioedema (HAE)
Phase 3Active
Key Facts
About Intellia Therapeutics
Intellia Therapeutics is a leader in translating Nobel Prize-winning CRISPR/Cas9 technology into transformative genomic medicines. The company's strategy leverages a dual-platform approach—in vivo and ex vivo editing—to advance a pipeline targeting rare genetic diseases like hereditary angioedema (HAE) and ATTR amyloidosis, with key programs in late-stage development. Backed by a strong intellectual property foundation and a strategic partnership with Regeneron, Intellia is building toward becoming a fully integrated, commercial-stage biopharmaceutical company.
View full company profileTherapeutic Areas
Other Hereditary Angioedema (HAE) Drugs
| Drug | Company | Phase |
|---|---|---|
| HAE Treatment | Cycle Pharmaceuticals | Commercial |
| Donidalorsen (IONIS-PKK-LRx) | Ionis Pharmaceuticals | Phase 3 |